Pair Name | Sanguinarium, Gefitinib | ||
Phytochemical Name | Sanguinarium (PubChem CID: 5154 ) | ||
Anticancer drug Name | Gefitinib (PubChem CID: 123631 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Sanguinarium, Gefitinib | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Redox imbalance | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BCL-xL | hsa598 | |
Up-regulation | Expression | NOX3 | KEGG ID N.A. | |
In Vitro Model | NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 |
In Vivo Model | The mixture of 1×10⁶ H1975 cells was resuspended in 100 μL of RPMI 1640 medium and 50 μL of Matrigel and injected into the armpit of the right forelimb of 6- to 8-week-old nude mice. Five days later, the mice with tumor formation were administered with sanguinarine via i.p. injection and afatinib via intragastric administration 5 days/week 32 for consecutive days. The tumor growth was monitored every 3–4 days using calipers. | |||
Result | Targeting EGFR by elevating ROS and redox imbalance is a potential new strategy to develop a new EGFR inhibitor for TKI-resistant patients with a wide therapeutic window between EGFR(T790M) and EGFR(WT) |
No. | Title | Href |
---|---|---|
1 | Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation. Antioxid Redox Signal. 2016;24(5):263-279. doi:10.1089/ars.2015.6420 | Click |